, Pharmacology gIllustrated g Reviews g7th gEdition gWhalen gTest
Bank gTABLE gOF gCONTENT
g
Chapter g 1: g Pharmacokinetics
Chapter g2: gDrug–Receptor gInteractions gand gPharmacodynamics
g Chapter g3: g The g Autonomic gNervous gSystem
Chapter g4: gCholinergic gAgonists
gChapter g5: gCholinergic
gAntagonists gChapter g6:
gAdrenergic gAgonists gChapter g7:
gAdrenergic gAntagonists
Chapter g8: gDrugs gfor gNeurodegenerative gDiseases
gChapter g9: gAnxiolytic gand gHypnotic gDrugs
Chapter g10: gAntidepressants
gChapter g11: gAntipsychotic gDrugs
gChapter g12: gDrugs gfor gEpilepsy
gChapter g13: gAnesthetics
Chapter g 14: g Opioids
Chapter g15: gDrugs gof gAbuse
gChapter g16: gCNS gStimulants
gChapter g17: gAntihypertensives
gChapter g18: gDiuretics
Chapter g 19: g Heart g Failure
Chapter g20: gAntiarrhythmics
gChapter g21: gAntianginal gDrugs
Chapter g22: gAnticoagulants gand gAntiplatelet gAgents
g Chapter g23: gDrugs gfor gHyperlipidemia
Chapter g24: gPituitary gand gThyroid
gChapter g25: gDrugs gfor gDiabetes
Chapter g26: gEstrogens gand gAndrogens
gChapter g27: gAdrenal gHormones
Chapter g 28: g Drugs g for g Obesity
Chapter g29: gDrugs gfor gDisorders gof gthe gRespiratory gSystem
g Chapter g30: gAntihistamines
Chapter g31: gGastrointestinal gand gAntiemetic gDrugs
gChapter g32: gDrugs gfor gUrologic g Disorders
Chapter g 33: g Drugs g for g Anemia
Chapter g34: gDrugs gfor gDermatologic gDisorders
gChapter g35: gDrugs gfor gBone gDisorders
Chapter g36: gAnti-inflammatory, gAntipyretic, gand g Analgesic gAgents
g Chapter g37: g Principles gof g Antimicrobial g Therapy
Chapter g 38: g Cell g Wall g Inhibitors
Chapter g 39: g Protein g Synthesis g Inhibitors
Chapter g40: gQuinolones, gFolic gAcid g Antagonists, g and g Urinary g Tract gAntiseptics
gChapter g41: gAntimycobacterial gDrugs
Chapter g42: gAntifungal gDrugs
gChapter g43: gAntiprotozoal gDrugs
gChapter g44: gAnthelmintic gDrugs
gChapter g45: gAntiviral gDrugs
Chapter g 46: g Anticancer g Drugs
Chapter g47: gImmunosuppressants
Chapter 48: Clinical Toxicology
Plusbay.Plus
,Plusbay.Plus
, 3. The gnurse gis gteaching ga gpatient gwho gwill gbe gdischarged ghome gwith ga gprescription gfor gan
enteric- gcoated gtablet. gWhich gstatement gby gthe gpatient g indicates gunderstanding gof gthe
g
g teaching?
a. Igmay gcrush gthe gtablet gand g put git gin gapplesauce gto gimprove gabsorption.
b. I gshould g consume gacidic gfoodsgto genhance gabsorption gof gthis gmedication.
c. I g should g expect g a gdelay gin gonset g of gthe gdrugs geffects gafter gtaking gthe gtablet.
d. I gshould gtake gthis gmedication gwith ghigh-fat gfoodsgto gimprove gits
gaction. gANS: gC
Enteric-coated gtablets gresist gdisintegration gin gthe gacidic genvironment gof gthe gstomach gand
g disintegrate gwhen gthey greach gthe gsmall gintestine. gThere gis gusually gsome gdelay gin gonset gof
g actions gafter gtaking gthese gmedications. gEnteric-coated gtablets gshould gnot gbe gcrushed gor
g chewed, gwhich gwould galter gthe gtime gand glocation gof gabsorption. gAcidic gfoods gwill gnot genhance
the gabsorption gof gthe gmedication. gThe gpatient gshould gnot gto geat ghigh-fat gfood gbefore gingesting
g
g an genteric-coated gtablet, gbecause ghigh-fat gfoods gdecrease gthe gabsorption grate.
DIF: gCOGNITIVE gLEVEL: gApplying g(Application) gREF: gdm g3
g TOP: gNURSING gPROCESS: gNursing gIntervention
MSC: gNCLEX: gPhysiological gIntegrity: gPharmacological gand g Parenteral gTherapies
4. A gpatient gwho gis gnewly gdiagnosed gwith gtype g1 gdiabetes gmellitus gasks gwhy ginsulin gmust gbe
g given gby gsubcutaneous ginjection ginstead gof gbygmouth. gThe gnurse gwillgexplain gthat gthis gis
because
g
a. absorption gis g diminished g bygthe gfirst-pass geffects gin gthe gliver.
b. absorption gis gfaster gwhen ginsulin gis ggiven gsubcutaneously.
c. digestive genzymes gin gthe ggastrointestinal gtract gprevent gabsorption.
d. the goral gformgis gless gpredictable gwith gmore gadverse
effects. gANS: gC
g
Insulin, ggrowth ghormones, gand gother gprotein-based gdrugs gare gdestroyed gin gthe gsmall gintestine gby
g digestive genzymes gand gmust gbe ggiven gparenterally. gBecause ginsulin gis gdestroyed gby gdigestive
g enzymes, git gwould gnot gmake git gto gthe gliver gfor gmetabolism gwith ga gfirst-pass geffect.
Subcutaneous gtissue ghas gfewer gblood gvessels, gso gabsorption gis gslower gin gsuch gtissue. gInsulin gis
g
g given gsubcutaneously gbecause git gis gdesirable gto ghave git gabsorb gslowly.
DIF: gCOGNITIVE gLEVEL: gUnderstanding g(Comprehension) gREF: gdm g3
g TOP: gNURSING gPROCESS: gNursing gIntervention: gPatient gTeaching
MSC: gNCLEX: gPhysiological gIntegrity: gPharmacological gand g Parenteral gTherapies
Page g 2 g of g 507
Bank gTABLE gOF gCONTENT
g
Chapter g 1: g Pharmacokinetics
Chapter g2: gDrug–Receptor gInteractions gand gPharmacodynamics
g Chapter g3: g The g Autonomic gNervous gSystem
Chapter g4: gCholinergic gAgonists
gChapter g5: gCholinergic
gAntagonists gChapter g6:
gAdrenergic gAgonists gChapter g7:
gAdrenergic gAntagonists
Chapter g8: gDrugs gfor gNeurodegenerative gDiseases
gChapter g9: gAnxiolytic gand gHypnotic gDrugs
Chapter g10: gAntidepressants
gChapter g11: gAntipsychotic gDrugs
gChapter g12: gDrugs gfor gEpilepsy
gChapter g13: gAnesthetics
Chapter g 14: g Opioids
Chapter g15: gDrugs gof gAbuse
gChapter g16: gCNS gStimulants
gChapter g17: gAntihypertensives
gChapter g18: gDiuretics
Chapter g 19: g Heart g Failure
Chapter g20: gAntiarrhythmics
gChapter g21: gAntianginal gDrugs
Chapter g22: gAnticoagulants gand gAntiplatelet gAgents
g Chapter g23: gDrugs gfor gHyperlipidemia
Chapter g24: gPituitary gand gThyroid
gChapter g25: gDrugs gfor gDiabetes
Chapter g26: gEstrogens gand gAndrogens
gChapter g27: gAdrenal gHormones
Chapter g 28: g Drugs g for g Obesity
Chapter g29: gDrugs gfor gDisorders gof gthe gRespiratory gSystem
g Chapter g30: gAntihistamines
Chapter g31: gGastrointestinal gand gAntiemetic gDrugs
gChapter g32: gDrugs gfor gUrologic g Disorders
Chapter g 33: g Drugs g for g Anemia
Chapter g34: gDrugs gfor gDermatologic gDisorders
gChapter g35: gDrugs gfor gBone gDisorders
Chapter g36: gAnti-inflammatory, gAntipyretic, gand g Analgesic gAgents
g Chapter g37: g Principles gof g Antimicrobial g Therapy
Chapter g 38: g Cell g Wall g Inhibitors
Chapter g 39: g Protein g Synthesis g Inhibitors
Chapter g40: gQuinolones, gFolic gAcid g Antagonists, g and g Urinary g Tract gAntiseptics
gChapter g41: gAntimycobacterial gDrugs
Chapter g42: gAntifungal gDrugs
gChapter g43: gAntiprotozoal gDrugs
gChapter g44: gAnthelmintic gDrugs
gChapter g45: gAntiviral gDrugs
Chapter g 46: g Anticancer g Drugs
Chapter g47: gImmunosuppressants
Chapter 48: Clinical Toxicology
Plusbay.Plus
,Plusbay.Plus
, 3. The gnurse gis gteaching ga gpatient gwho gwill gbe gdischarged ghome gwith ga gprescription gfor gan
enteric- gcoated gtablet. gWhich gstatement gby gthe gpatient g indicates gunderstanding gof gthe
g
g teaching?
a. Igmay gcrush gthe gtablet gand g put git gin gapplesauce gto gimprove gabsorption.
b. I gshould g consume gacidic gfoodsgto genhance gabsorption gof gthis gmedication.
c. I g should g expect g a gdelay gin gonset g of gthe gdrugs geffects gafter gtaking gthe gtablet.
d. I gshould gtake gthis gmedication gwith ghigh-fat gfoodsgto gimprove gits
gaction. gANS: gC
Enteric-coated gtablets gresist gdisintegration gin gthe gacidic genvironment gof gthe gstomach gand
g disintegrate gwhen gthey greach gthe gsmall gintestine. gThere gis gusually gsome gdelay gin gonset gof
g actions gafter gtaking gthese gmedications. gEnteric-coated gtablets gshould gnot gbe gcrushed gor
g chewed, gwhich gwould galter gthe gtime gand glocation gof gabsorption. gAcidic gfoods gwill gnot genhance
the gabsorption gof gthe gmedication. gThe gpatient gshould gnot gto geat ghigh-fat gfood gbefore gingesting
g
g an genteric-coated gtablet, gbecause ghigh-fat gfoods gdecrease gthe gabsorption grate.
DIF: gCOGNITIVE gLEVEL: gApplying g(Application) gREF: gdm g3
g TOP: gNURSING gPROCESS: gNursing gIntervention
MSC: gNCLEX: gPhysiological gIntegrity: gPharmacological gand g Parenteral gTherapies
4. A gpatient gwho gis gnewly gdiagnosed gwith gtype g1 gdiabetes gmellitus gasks gwhy ginsulin gmust gbe
g given gby gsubcutaneous ginjection ginstead gof gbygmouth. gThe gnurse gwillgexplain gthat gthis gis
because
g
a. absorption gis g diminished g bygthe gfirst-pass geffects gin gthe gliver.
b. absorption gis gfaster gwhen ginsulin gis ggiven gsubcutaneously.
c. digestive genzymes gin gthe ggastrointestinal gtract gprevent gabsorption.
d. the goral gformgis gless gpredictable gwith gmore gadverse
effects. gANS: gC
g
Insulin, ggrowth ghormones, gand gother gprotein-based gdrugs gare gdestroyed gin gthe gsmall gintestine gby
g digestive genzymes gand gmust gbe ggiven gparenterally. gBecause ginsulin gis gdestroyed gby gdigestive
g enzymes, git gwould gnot gmake git gto gthe gliver gfor gmetabolism gwith ga gfirst-pass geffect.
Subcutaneous gtissue ghas gfewer gblood gvessels, gso gabsorption gis gslower gin gsuch gtissue. gInsulin gis
g
g given gsubcutaneously gbecause git gis gdesirable gto ghave git gabsorb gslowly.
DIF: gCOGNITIVE gLEVEL: gUnderstanding g(Comprehension) gREF: gdm g3
g TOP: gNURSING gPROCESS: gNursing gIntervention: gPatient gTeaching
MSC: gNCLEX: gPhysiological gIntegrity: gPharmacological gand g Parenteral gTherapies
Page g 2 g of g 507
